Please Wait.....
Report
France Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 100 Pages I Mordor Intelligence
France Drug Delivery Devices Market Analysis
The France drug delivery devices market size stands at USD 6.90 billion in 2025 and is projected to rise to USD 10.63 billion by 2030, reflecting a 9.03% CAGR. Rapid expansion is fueled by connected-device innovation, growth in biologic and biosimilar therapies, and national e-health programs that encourage self-administration. Manufacturers gain momentum from France's robust contract development and manufacturing organization (CDMO) ecosystem, while high chronic-disease prevalence sustains steady demand. Regulatory initiatives such as early reimbursement pathways for digital devices shorten time to market, although complex pricing caps and EU Medical Device Regulation (MDR) compliance remain notable obstacles. Together, these factors position the France drug delivery devices market as a key growth engine within Europe.
France Drug Delivery Devices Market Trends and Insights
Shift to Home-Based Care & Self-Administration
France is prioritizing homecare, and the end-user segment already shows a 13.03% CAGR, the highest across settings. The National eHealth Roadmap (2023-2027) backs connected devices that transmit real-time dosing data and support remote consultations.Sanofi's Solosmart sensor, available in 21,000 pharmacies, captures insulin injection records and integrates seamlessly with patient apps. Such devices redefine competition by elevating usability and data connectivity to the same level as pharmacological performance, driving France drug delivery devices market adoption.
Expansion of Biologic & Biosimilar Injectables
High-viscosity biologics need specialized delivery formats. Novo Nordisk invested EUR2.1 billion in its Chartres site to double insulin capacity. BD's Neopak XtraFlow syringe targets these formulations, highlighting collaborative innovation between pharma and device makers. Growing biologic pipelines ensure sustained demand in the France drug delivery devices market, particularly for self-injectors and wearable pumps.
Complex Reimbursement Price Caps
France differentiates device and service payments and caps distributor margins, extending the average approval-to-reimbursement period to 12.9 months, compared with 6 months in Switzerland and 7.4 months in Germany. The SMR/ASMR scoring method can exclude low-benefit products from coverage, slowing revenue for combination devices and tempering growth within the France drug delivery devices market.
Other drivers and restraints analyzed in the detailed report include:
Technological Advancements and e-Health Strategy / Robust CDMO & Device Manufacturing Ecosystem / Stringent Regulatory Framework /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Injectables retained 45.34% share in 2024, supported by steady biologic usage and continuous upgrades in prefilled syringes and autoinjectors. BD's RFID-enabled iDFill syringe shown at Pharmapack 2025 underscores a focus on traceability and patient safety. Despite this lead, implantables are forecast to rise at 11.89% CAGR to 2030, reflecting patient preference for longer dosing intervals and emerging hydrogel reservoirs that stretch semaglutide dosing to monthly schedules. This momentum positions implantables as a disruptive force inside the France drug delivery devices market.
Transdermal patches, ocular inserts, and intranasal systems broaden therapeutic choices. The nasal route, highlighted by Pfizer's approved Zavzpret spray for migraine, demonstrates expanding utility beyond respiratory therapy. These additive modalities bolster device diversity and reinforce overall resilience of the France drug delivery devices market.
Injectables accounted for 58.12% of France drug delivery devices market size in 2024, favored for precision dosing across chronic illnesses. Continuous needle-design refinements improve user comfort, strengthening retention in both hospital and home settings.
Inhalation is slated for 9.56% CAGR between 2025-2030. Partnerships such as Chiesi-Affibody on inhaled biologics widen respiratory portfolios. Nasal delivery gains traction for central nervous system targets; French start-up Lovaltech advances an intranasal vaccine platform under France 2030 funding. These advances expand treatment horizons and feed sustained growth within the France drug delivery devices market.
France Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps and More), Route of Administration (Injectable, Inhalational, Transdermal and More), Application (Diabetes, Oncology, Cardiovascular Diseases and More), End User (Hospitals, Ambulatory Surgical & Specialty Clinics and More). The Market and Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Sanofi / Beckton Dickinson / Roche / Novo Nordisk / Johnson&Johnson / Solventum / Baxter / Bayer / Pfizer / Terumo / Gerresheimer / Nemera / AptarGroup, Inc. / West Pharmaceutical Services / Ypsomed / Vetter Pharma-Fertigung / B. Braun / Owen Mumford / Insulet / Tandem Diabetes Care / Eli Lilly and Company / Recipharm / Unither Pharmaceuticals /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Shift to Home-Based Care & Self-Administration
4.2.2 Expansion of Biologic & Biosimilar Injectables
4.2.3 Technological Advancements and e-Health Strategy Accelerating Connected Devices
4.2.4 Robust CDMO & Device Manufacturing Ecosystem
4.2.5 High Burden of Chronic Diseases
4.2.6 Supporting Reforms and Regulations Fueling Demand for Drug Delivery Device
4.3 Market Restraints
4.3.1 Complex Reimbursement Price Caps
4.3.2 Stringent Regulatory Framework
4.3.3 Limitations Associated with Different Devices and Risks
4.3.4 Issues Related to Fragmented Hospital Tendering and Generics Affecting Price of Drug Device Combination
4.4 Value / Supply-Chain Analysis
4.5 Regulatory and Technological Outlook
4.6 Porter's Five Forces Analysis
4.6.1 Bargaining Power of Suppliers
4.6.2 Bargaining Power of Buyers
4.6.3 Threat of New Entrants
4.6.4 Threat of Substitutes
4.6.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Device Type
5.1.1 Injectable Delivery Devices
5.1.2 Inhalation Delivery Devices
5.1.3 Infusion Pumps
5.1.4 Transdermal Patches
5.1.5 Implantable Drug Delivery Systems
5.1.6 Ocular Inserts & Delivery Implants
5.1.7 Nasal & Buccal Delivery Devices
5.2 By Route of Administration
5.2.1 Injectable
5.2.2 Inhalation
5.2.3 Transdermal
5.2.4 Oral Mucosal (Buccal & Sublingual)
5.2.5 Ocular
5.2.6 Nasal
5.3 By Application
5.3.1 Diabetes
5.3.2 Oncology
5.3.3 Cardiovascular Diseases
5.3.4 Respiratory Diseases
5.3.5 Infectious Diseases
5.3.6 Auto-Immune & Inflammatory Disorders
5.3.7 CNS Disorders
5.4 By End User
5.4.1 Hospitals
5.4.2 Ambulatory Surgical & Specialty Clinics
5.4.3 Homecare Settings / Self-Use
5.4.4 Retail & Online Pharmacies
6 Competitive Landscape
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.4.1 Sanofi
6.4.2 Becton, Dickinson and Company
6.4.3 F. Hoffmann-La Roche AG
6.4.4 Novo Nordisk A/S
6.4.5 Johnson & Johnson
6.4.6 Solventum
6.4.7 Baxter International Inc.
6.4.8 Bayer AG
6.4.9 Pfizer Inc.
6.4.10 Terumo Corporation
6.4.11 Gerresheimer AG
6.4.12 Nemera
6.4.13 AptarGroup, Inc.
6.4.14 West Pharmaceutical Services
6.4.15 Ypsomed AG
6.4.16 Vetter Pharma-Fertigung
6.4.17 B. Braun Melsungen AG
6.4.18 Owen Mumford Ltd.
6.4.19 Insulet Corporation
6.4.20 Tandem Diabetes Care
6.4.21 Eli Lilly and Company
6.4.22 Recipharm AB
6.4.23 Unither Pharmaceuticals
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security